Shares in local drugmaker SCI Pharmtech Inc (SCI, 旭富製藥) rose 0.5 percent to NT$60.8 yesterday, weaker than the TAIEX’s 0.85 percent increase, Taiwan Stock Exchange data showed, one day after the company trimmed its capital by NT$380,000 (US$11,988).
The Taoyuan-based company cut its capital by buying back 38,000 common shares from employees and therefore raised its net worth to NT$31.28 per share, from the previous NT$31.27, according to its stock filing.
As of yesterday, SCI shares had fallen 2.09 percent this year, more than the main bourse’s 0.6 percent retreat and the chemical sector’s 1.3 percent slide, the TAIEX said.
Still, Fubon Securities Co (富邦證券) maintained a “buy” rating for the drugmaker, as the company is set to benefit from order reallocations by some clients and its sales of primary drug pipelines remain healthy.
“We maintain our positive earnings outlook for its main drug pipelines,” Fubon research analyst Heather Chang (張雅雯) said in a report.
SCI is an affiliate of Mercuries & Associates Ltd (三商行), whose business interests include Mercuries Life Insurance Co (三商美邦人壽), Mercuries Data Systems Ltd (三商電腦), supermarket chain Simple Mart (美廉社), shoe retailer Family Shoes (鞋全家福), beef noodle chain Sanshang Chiaofu (三商巧福) and other ventures.
The drugmaker is one of the nation’s leading pharmaceutical active-ingredient providers and has expanded into diet, anti-depression and HIV/AIDS medications in recent years to diversify its revenue sources.
SCI is poised to benefit from order reallocations by certain customers, Chang said, adding that primary drug pipelines’ sales look healthy, with a still-intact growth history from gross margin expansions and long-term operations.
The active-pharmaceutical ingredients category used to make hydroxychloroquine, a medicine used to treat or prevent malaria, lupus and rheumatoid arthritis, is on course to outperform estimates, with shipments forecast to surge from 3.3 tonnes last year to 20 tonnes this year, the report said.
At the same time, SCI’s antidepressants unit has struck a new deal with an Indian pharmaceutical firm, with initial shipments to begin soon, the report said.
“We expect antidepressant sales to deliver outstanding growth from mid-year on” after SCI secured a position last year as the secondary supplier for the generic formulation of US drugmaker Eli Lilly and Co’s off-patent fluoxetine at a more competitive price.
SCI posted NT$93 million in revenue last month, down 8.86 percent from the same period last year, the stock filing showed.
As of September last year, pre-tax income totaled NT$266.88 million, or NT$3.15 earnings per share, the filing said.
BUSINESS UPDATE: The iPhone assembler said operations outlook is expected to show quarter-on-quarter and year-on-year growth for the second quarter Hon Hai Precision Industry Co (鴻海精密) yesterday reported strong growth in sales last month, potentially raising expectations for iPhone sales while artificial intelligence (AI)-related business booms. The company, which assembles the majority of Apple Inc’s smartphones, reported a 19.03 percent rise in monthly sales to NT$510.9 billion (US$15.78 billion), from NT$429.22 billion in the same period last year. On a monthly basis, sales rose 14.16 percent, it said. The company in a statement said that last month’s revenue was a record-breaking April performance. Hon Hai, known also as Foxconn Technology Group (富士康科技集團), assembles most iPhones, but the company is diversifying its business to
Apple Inc has been developing a homegrown chip to run artificial intelligence (AI) tools in data centers, although it is unclear if the semiconductor would ever be deployed, the Wall Street Journal reported on Monday. The effort would build on Apple’s previous efforts to make in-house chips, which run in its iPhones, Macs and other devices, according to the Journal, which cited unidentified people familiar with the matter. The server project is code-named ACDC (Apple Chips in Data Center) within the company, aiming to utilize Apple’s expertise in chip design for the company’s server infrastructure, the newspaper said. While this initiative has been
GlobalWafers Co (環球晶圓), the world’s No. 3 silicon wafer supplier, yesterday said that revenue would rise moderately in the second half of this year, driven primarily by robust demand for advanced wafers used in high-bandwidth memory (HBM) chips, a key component of artificial intelligence (AI) technology. “The first quarter is the lowest point of this cycle. The second half will be better than the first for the whole semiconductor industry and for GlobalWafers,” chairwoman Doris Hsu (徐秀蘭) said during an online investors’ conference. “HBM would definitely be the key growth driver in the second half,” Hsu said. “That is our big hope
The consumer price index (CPI) last month eased to 1.95 percent, below the central bank’s 2 percent target, as food and entertainment cost increases decelerated, helped by stable egg prices, the Directorate-General of Budget, Accounting and Statistics (DGBAS) said yesterday. The slowdown bucked predictions by policymakers and academics that inflationary pressures would build up following double-digit electricity rate hikes on April 1. “The latest CPI data came after the cost of eating out and rent grew moderately amid mixed international raw material prices,” DGBAS official Tsao Chih-hung (曹志弘) told a news conference in Taipei. The central bank in March raised interest rates by